{
    "2018-01-29": [
        [
            {
                "time": "",
                "original_text": "乐普医疗：预计2017年净利润同比增长30.0%-40%",
                "features": {
                    "keywords": [
                        "乐普医疗",
                        "净利润",
                        "同比增长",
                        "30%",
                        "40%"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医疗"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "乐普医疗：2017年度业绩报告预告",
                "features": {
                    "keywords": [
                        "乐普医疗",
                        "2017年度",
                        "业绩报告",
                        "预告"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医疗"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "乐普医疗预计2017年度净利8.8亿元-9.5亿元",
                "features": {
                    "keywords": [
                        "乐普医疗",
                        "2017年度",
                        "净利",
                        "8.8亿元",
                        "9.5亿元"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医疗"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "这些非周期性公司业绩预增至少30% 估值将降至20倍以下(名单)",
                "features": {
                    "keywords": [
                        "非周期性公司",
                        "业绩预增",
                        "30%",
                        "估值",
                        "20倍以下"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医疗",
                        "其他行业"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "医疗保健：3种CAR-T细胞制剂再被纳入优先审评",
                "features": {
                    "keywords": [
                        "医疗保健",
                        "CAR-T细胞制剂",
                        "优先审评"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医疗"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            }
        ]
    ]
}